Abstract Most studies that have examined neuropsychological impairments associated with human immunodeficiency virus (HIV) have focused on males, yet females represent one of the largest groups of newly infected patients. Further, few studies have examined neuropsychological performance and neuroimaging outcomes among females compared to males in the modern era of highly active anti-retroviral therapy (HAART). The present study investigated neuropsychological performance and brain volumetrics among HIV+ males (n= 93) and females (n=44) on stable HAART compared to HIV seronegative (HIV−) males (n= 42) and females (n =49). Results revealed a significant effect of HIV on neuropsychological performance and neuroimaging measures. An effect of gender, independent of HIV status, was also observed for neuroimaging measures but not neuropsychological performance. Additionally, no significant differences in neuropsychological performance or brain volumetrics were seen between HIV+ males and females. No significant interaction was observed between HIV and gender on either neuropsychological or neuroimaging indices. Our results suggest that both HIV+ males and females treated with HAART experience similar outcomes in terms of brain integrity.
Introduction
Human immunodeficiency virus (HIV) infects the central nervous system (CNS) and disrupts both gray (GM) and white matter (WM) regions of the brain (Becker et al. 2011; Kumar et al. 2011; Thompson et al. 2005) . Common neuropsychological abnormalities exhibited by HIV-infected (HIV+) patients include deficits in memory, attention, executive function, information processing speed, and psychomotor speed (Reger et al. 2002; Grant et al. 1999; Woods et al. 2009; Baker et al. 2014) . These neuropsychological abnormalities correlate with indices of brain integrity on magnetic resonance imaging (MRI) including alterations in WM microstructure (Pfefferbaum et al. 2006 (Pfefferbaum et al. , 2007 Thurnher et al. 2005; Ragin et al. 2005; Chang et al. 2008) , gross atrophy (Archibald et al. 2004; Jernigan et al. 1993) , and cortical and callosal thinning (Thompson et al. 2005; Jernigan et al. 1993; Goodkin et al. 1997; Mason et al. 1998; Paul et al. 2002; Tate et al. 2010) . Despite treatment with highly active anti-retroviral therapy (HAART), HIV-associated cognitive difficulties can be observed and lead to reduced overall quality of life in this population (Woods et al. 2009; Heaton et al. 2004) .
Research conducted on cognitive difficulties related to HIV has primarily focused on males, especially men who have sex with men (Robertson et al. 2004; Maki and Martin-Thormeyer 2009; Molsberry et al. 2015; Chang et al. 2013; Becker et al. 2009; Miller et al. 1990; van Gorp et al. 1994 ). However, females represent a significant percentage of HIV infections and account for over 25 % of new HIV/AIDS diagnoses in the USA (Centers for Disease Control and Prevention 2011). Globally, females constitute more than half of the HIV/ AIDS population and the prevalence of HIV is twofold greater for younger females than males (15-24 years old; Joint United Nations Programme on HIV/AIDS 2013). Collectively, these data highlight the importance of research that focuses on the health outcomes among females infected with HIV.
HIV+ females may be particularly susceptible to cognitive impairment due to interactions between host and viral factors (Wojna et al. 2006) . For example, depression is more prevalent in HIV+ females than males (Pereira and Canavarro 2011) and is associated with greater immune compromise and disease progression (Hestad et al. 2009 ). Additionally, females are at a higher risk of experiencing early life stress (ELS) than males (Spies et al. 2012) . Common ELS events that have been shown to be prevalent in HIV+ individuals, particularly HIV+ females, include neglect and physical, emotional, and sexual abuse (Clark et al. 2012) . Previous ELS events have been linked to significant memory and processing speed impairment in HIV+ females (Spies et al. 2012; Clark et al. 2012) . Given the increased risk of traumatic events and depression among females compared to males, it is possible that HIV+ females have an increased risk of neuropsychological abnormalities.
Studies examining the relationship between gender and cognition in HIV+ populations have produced mixed results with some studies reporting significant effects (Robertson et al. 1996; Martin et al. 2011; Hestad et al. 2012; Grant et al. 2014) and others reporting no impact of gender on brain integrity in HIV (Robertson et al. 2004; Ances et al. 2006; Maki et al. 2015; Pfefferbaum et al. 2006 Pfefferbaum et al. , 2007 . Relatedly, only a few studies have examined potential gender differences in brain volume among seropositive individuals and these studies have not revealed significantly different outcomes between males and females infected with HIV (Pfefferbaum et al. 2006 (Pfefferbaum et al. , 2007 Ances et al. 2006; Ge et al. 2003) . Importantly, with one exception (Maki et al. 2015) , most of these investigations were conducted prior to revised HAART guidelines. Recent advances in our understanding of HAART dosing (Caniglia et al. 2014; Willig et al. 2008; Kauf et al. 2008; Robertson et al. 2012) as well as enhanced HIV clinical management (Vellozzi et al. 2009 ) have improved HIV clinical care outcomes. In a recent study evaluating the cognitive profile of HIV+ females, HIV status had significant effects on verbal learning and memory and psychomotor tasks (Maki et al. 2015) . However, additional variables including age, years of education, reading level, and race were more strongly associated with neuropsychological profile than serostatus. Despite the large sample size and design of the study, it is necessary to extend these findings by directly comparing the neuropsychological and neuroimaging profile of both seropositive males and females with similar demographics, HIV treatment, and comorbidities. The aim of the current study was to investigate whether gender was associated with an increased risk for poor brain integrity (both cognitive performance and brain volumetrics) among HIV+ individuals.
Methods

Participants
A total of 228 individuals were included in this study. Participants were classified into four groups consisting of (1) 44 HIV+ females, (2) 49 HIV uninfected (HIV−) females, (3) 93 HIV+ males, and (4) 42 HIV− males (Table 1) . Participants were recruited from the Washington University School of Medicine (WUSM) Infectious Disease Clinic in Saint Louis, the WUSM AIDS Clinical Trial Group (ACTG) community medical providers and local organizations. All HIV+ participants were infected for greater than 4 months and were on stable HAART for at least 3 months. Exclusion criteria for all participants included fewer than 9 years of education, history of loss of consciousness >30 min, claustrophobia, seizures, developmental delays, metal implants in the head, or any other contraindication for MRI. Participants with a selfreported history of substance abuse/dependence within the last 6 months (including alcohol) or positive urine test for illicit drug use, conducted on the day of testing, were excluded. Participants with a Beck Depression Inventory-II (BDI-II; Beck and Steer 1996) total score >29 were also excluded from participation. All participants provided informed consent and were financially compensated for their participation. The WUSM Institutional Review Board (IRB) approved this study.
Screening measures
All HIV− controls were administered a rapid oral HIV buccal test to confirm negative result at the time of enrollment. All participants underwent a urine drug screen and females were administered a pregnancy test.
HIV clinical factors
A neuromedical examination was performed on all participants at the time of enrollment. Lab values including plasma CD4 T cell count and plasma HIV RNA levels were collected within 3 months of enrollment for all HIV+ participants. The majority of HIV+ males (72/93) and females (37/44) had undetectable plasma viral loads (<50 copies/mL). Nadir plasma CD4 T cell counts were obtained by patient self-report and confirmed by medical records when available.
Beck Depression Inventory
Current depression symptomology was assessed using the BDI-II. All participants completed the self-report inventory according to standard procedures.
Neuropsychological assessment
Subjects were administered a neuropsychological battery consisting of measures sensitive to neurocognitive impairment associated with HIV (Antinori et al. 2007; Baker et al. 2014) . Assessments were completed the same day as the MRI. Standard testing procedures were utilized to assess three cognitive domains including verbal learning and memory, executive functioning, and psychomotor/processing speed. Raw scores on each measure were recorded but were not normed as these measures include correction for potential differences in gender. The following measures were used to evaluate neuropsychological functioning:
i. Verbal Learning: total number of correct responses from three learning trials of the Hopkins Verbal Learning TestRevised (HVLT-R; Benedict et al. 1998; Brandt and Benedict, 2001 ). Verbal Memory: total number of correct responses from the Hopkins Verbal Learning Test-Revised delayed recall trial (HVLT-R delay; Benedict et al. 1998; Brandt and Benedict 2001) . (Borkowski et al. 1967) , and total correct on Verb Fluency (Piatt et al. 1999 ). iii. Psychomotor Speed/Processing Speed: correct number of responses on the Digit-Symbol Coding task (Wechsler 1997) ; time to completion on the Trail Making Test, Part A (TMT-A; Reitan and Davison 1974) and time to completion on the Grooved Pegboard Test non-dominant (ND) hand (Klove 1963) .
Neuroimaging
All images were acquired using a 3-T Siemens Tim Trio whole body MR scanner (Siemens AG, Erlangen Germany) with a 12-channel transmit/receive head coil. Structural images were obtained using a T1-weighted three-dimensional magnetization-prepared rapid acquisition gradient echo (MP-RAGE) sequence with the following parameters: time of repetition (TR)=2400 ms, echo time (TE)=3.16 ms, inversion time (TI)=1000 ms, flip angle=8°, 162 slices, and voxel size=1×1×1 mm 3 . All images were acquired in the sagittal plane. Motion was minimized by instructing participants to fixate on a plus sign centered on the screen. Volumes within specific predefined regions of interest (ROIs) were quantified using the FreeSurfer software suite (v5.1) (Martinos Center, Harvard University, Boston, MA, USA; http://surfer.mmr.mgh.harvard.edu). Individual MP-RAGE scans were transformed into a template space, the skull was removed, and the brain segmented into WM, GM, and ventricles. A surface deformation program was used to further segment brain regions into subcortical and cortical ROIs (Fischl et al. 2002; Desikan et al. 2006; Fischl and Dale 2000) . Images for all the subjects were then aligned onto a common atlas (MNI305; Fischl et al. 2002) . Strategic ROIs analyzed for this specific analysis comprised of areas that have been previously shown to be affected by HIV including the following: hippocampus, caudate, putamen, nucleus accumbens, corpus callosum, amygdala, total WM, and total GM (Fig. 1 ) (Thompson et al. 2005; Stout et al. 1998; Ances et al. 2012; Heaps et al. 2012; Ortega et al. 2013; Chang et al. 2011) . A trained rater (JMH) independently confirmed the segmentation of these ROIs making necessary manual edits when required. Each volume was normalized to total intracranial volume using a least square residual regression model ).
Statistical analysis
Primary analyses
All statistical analyses were conducted utilizing SPSS (Version 21). Independent sample t tests and chi-squared analyses were conducted to assess potential differences in age, education, gender, race, and depression score between the four groups ( Table 1) . The groups significantly differed with regard to age and therefore it was included as a covariate in all subsequent analyses. Depression scores were significantly higher in the HIV+ female group compared to the other groups; however, depression scores were not correlated with ROI volumes (r values ranging from −0.009 to 0.08; all p values >0.22). Additionally, depression scores were weakly correlated with verb fluency (r=0.15; p= 0.02) and TMT-A (r=0.15; p=0.02). Secondary analyses were conducted to correct for depression scores.
The HIV+ group was significantly older than the HIV− group; therefore, age was used as a covariate in all analyses comparing HIV+ versus HIV− individuals. The three cognitive domains of verbal learning and memory, psychomotor/ processing speed, and executive function were entered by domain in subsequent factorial Multivariate analyses of covariance (MANCOVAs) with age and race included as covariates. HIV serostatus and gender were entered as main effects, and the interaction between HIV serostatus and gender was also entered into the model. The raw scores on the measures for each cognitive domain were entered as dependent variables. Finally, univariate analyses were examined in order to determine individual dependent variable contributions to the main effects. The eight ROIs were entered into separate factorial analyses of covariance (ANCOVAs; with age as a covariate) as the primary outcome measures for the neuroimaging analysis.
Pearson's correlation analyses were conducted to determine the relationships between clinical markers of disease burden (CD4 and plasma viral load (VL)), brain volumetrics, and neuropsychological performance in the HIV+ group. Plasma CD4 (nadir and recent) and HIV VL were square root transformed natural log transformed, respectively, to achieve normal distributions for the correlation analyses.
Secondary analyses
MANCOVAs with depression, age, and race as covariates were conducted to assess the main effects of HIV status and gender on cognitive domains as well as the interaction between HIV and gender on these outcomes. Executive function and psychomotor/processing speed were entered by domain in subsequent factorial MANCOVAs. HIV serostatus and gender were entered as the independent variables as well as an HIV by gender interaction. The raw scores on the measures for each cognitive domain were entered as dependent variables. Finally, univariate analyses were examined in order to determine individual dependent variable contributions to the main effects. (Table 2) ). There was no significant main effect of gender on psychomotor/processing speed (Wilks' λ=0.969, F (3,200) =2.13, p=0.10, η 2 =0.03). Additionally, there was no significant interaction between HIV and gender in the psychomotor/processing domain (Wilks' λ=0.984, F (3,200) = 1.09, p=0.36, η 2 =0.02).
Results
Neuropsychological performance-primary analyses
Learning and memory
There was no effect of HIV (Wilks' λ=0.992, F (2,215) = 0.826, p=0.44, η 2 =0.008) or gender (Wilks' λ=0.992, F (2,215) = 0.895, p = 0.41, η 2 = 0.008) on learning and memory. In addition, there was no significant interaction between HIV and gender in the learning and memory domain (Wilks' λ = 0.99, F (2,213) = 1.05, p = 0.35, η 2 = 0.01). ) for HIV-infected (HIV+) and HIVuninfected (HIV−) groups. Lines within each box represent the mean values for volumes of each group within each of the following regions: a putamen; b amygdala; c white matter; d nucleus accumbens; e corpus callosum; f hippocampus; g caudate; h total gray matter. The effect of HIV on the corpus callosum does not survive false discovery rate (FDR) correction. However, for all other regions, the effect of HIV but not gender was significant after FDR correction
Neuropsychological performance-secondary analyses
To determine if the results were affected by depression, secondary analyses were conduced to examine the effect of HIV status and gender on neuropsychological performance in the executive function and psychomotor domains.
Executive function
After controlling for depression scores, age, and race, HIV+ individuals demonstrated poorer performance than seronegative controls on tests of executive function (F (4, 204) =4.11, p=0.003). Exploratory analysis revealed that HIV+ individuals performed significantly worse than seronegative controls on the L-N Seq task (F (1,213) =14.32, p = 0.016) and the verb fluency task (F (1, 213) = 13.51, p<0.001). However, there was no main effect of gender and no interaction between HIV and gender on executive function.
Psychomotor/processing speed
The main effect of HIV status on the psychomotor tests was not significant when accounting for depression in the model. Additionally, there was no main effect of gender and no interaction between HIV and gender on tests of psychomotor/ processing speed.
Brain imaging
A significant main effect of HIV status on brain volumetrics was observed for the following ROIs: total GM (F (1, 228) 9.97, p<0.002). The interaction between gender and HIV was not significant for any of the selected brain volumes. A secondary analysis that included depression scores as a covariate did not affect the significant main effects for the neuroimaging measures (Table 3 ). Pearson's correlation analyses examined the relationship between brain integrity measures (neuropsychological performance and volumetrics) and laboratory values (current plasma CD4 T cell count, nadir plasma CD4 T cell count, and plasma HIV RNA viral load) in the HIV+ group. There were no significant associations between the cognitive measures and laboratory values after controlling for multiple comparisons using a false discovery rate (FDR; min p value required 0.006, lowest p value=0.03). In general, laboratory values were not correlated with ROI volumes. Only a correlation between higher nadir CD4 and larger thalamus volume (r= 0.27, p=0.004) was preserved after correction for multiple comparisons.
Discussion
The present study investigated whether differences exist between males and females on measures of cognition and brain volumetrics among HIV+ individuals in the modern HAART era. Overall, we observed an effect of HIV on brain integrity measures. In addition, an effect of gender, independent of HIV status, was observed for some neuroimaging measures but not neuropsychological performance. Our study did not reveal any significant interactions between HIV and gender for neuropsychological performance or brain imaging measures. Specifically, no significant differences between males and females were evident on measures of executive function, psychomotor/processing speed, verbal learning and memory, or brain volumes across a number of ROIs that are often sensitive to the effects of HIV (Grant et al. 1999; Woods et al. 2009 ). Overall, our findings coincide with past research demonstrating no significant gender differences in cognitive status associated with HIV among patients examined in the pre-HAART era (Ge et al. 2003; Ances et al. 2006; Pfefferbaum et al. 2006 Pfefferbaum et al. , 2007 . The present study extends this literature by examining a cohort of patients on stable HAART.
In the pre-HAART era, some studies reported an increased risk for HIV-associated dementia (Chiesi et al. 1996a, b) and/ or encephalitis (Morlat et al. 1992) among HIV+ females at the time of AIDS diagnosis. Further, Robertson et al. (1996) observed greater neurocognitive dysfunction and abnormal visual-evoked potentials among HIV+ females compared to males. In the HAART era, HIV+ females exhibited significantly poorer performance on tasks of motor function and learning when compared to HIV− females, whereas no differences were revealed between HIV+ and HIV− males . Additional work conducted in Zambia reported that HIV+ females exhibited greater cognitive impairment compared to HIV+ males (Hestad et al. 2012) , an effect possibly driven by gender differences in access to health care and other resources as well as comorbid conditions experienced more frequently by females. Finally, a study at five major centers in the USA (CHARTER; CNS HIV Anti-Retroviral Therapy Effects Research) investigating disease progression demonstrated that asymptomatic HIV+ females showed a threefold increase in risk for developing more severe forms of cognitive impairment when compared to asymptomatic HIV+ males (Grant et al. 2014) .
In contrast to the literature cited above, other studies have reported no significant difference in the frequency or severity of cognitive dysfunction secondary to HIV according to gender. Bouwman et al. (1998) reported that intravenous drug use was a stronger predictor of cognitive impairment than gender among an HIV+ sample. Robertson et al. (2004) identified no effects of gender on cognitive outcomes at baseline or after a 3-year longitudinal follow-up. It is important to note that a large percentage of individuals in the latter study were not on HAART and therefore the results may not be generalizable to a cohort of patients on stable HAART regimens. The issue of treatment status is important, as pre-HAART outcomes may not generalize to the post-HAART era. Although our study and others have failed to show a significant difference between males and females, this is not to say that the groups perform equally or have equivalent changes with regard to brain integrity. To determine equivalence, additional statistical Alternatively, an effect of HIV serostatus was observed on cognitive measures with HIV+ individuals performing significantly worse on two measures of executive functioning (i.e., Verb Fluency and L-N Seq). Previous studies have demonstrated that neurocognitive impairment is present in HIV+ patients despite successful viral suppression and immune system improvements (Woods et al. 2009; Heaton et al. 2010; Antinori et al. 2007 ). Evidence of residual impairments in executive function is highly problematic given the importance of these cognitive skills for effective implementation of activities of daily living. Executive function predicts adherence to HIV medications, driving abilities, financial management, and related high-level instrumental activities of daily living (Rog et al. 2014; Thames et al. 2013; Cattie et al. 2012; Boyle et al. 2002 Boyle et al. , 2003 Tomaszewski et al. 2009; Scott et al. 2011) . The chronic nature of executive deficits and the importance of these skills to successfully engage in critical aspects of daily living underscore the need for interventions to improve executive skills among HIV+ individuals already on treatment.
In terms of brain volumetrics, the HIV+ group had significantly lower brain volumes in all ROIs when compared to HIV− controls. Evidence of residual brain volumetric abnormalities due to HIV among seropositive individuals on effective HAART is consistent with previous work (Thompson et al. 2005; Ances et al. 2006; Becker et al. 2011; Archibald et al. 2004) , and emphasizes the chronic nature of brain dysfunction associated with HIV. Results of the present study provide further evidence that these residual brain abnormalities that appear are similarly present in males and females. In this study, individuals were excluded if they reported a recent history of substance or alcohol abuse, yet this criterion may not have adequately controlled for the effects of remote substance or alcohol abuse. As such, future investigation including remote history of substance abuse disorders may reveal specific contributions of these disorders to brain integrity (Fama et al. 2014; Pfefferbaum et al. 2006 Pfefferbaum et al. , 2012 Jernigan et al. 2005; Teoh et al. 1993) .
Similarly, there were significant differences in brain volumetrics between males and females but no gender and HIV interaction. Overall, males displayed larger total GM volume, amygdala, putamen, and hippocampal regions when compared to females. Although neuroimaging studies have established similar sex-specific dimorphisms in healthy individuals (Lüders et al. 2002; Raz et al. 2001; Good et al. 2001) , few studies have been completed to date that were designed to examine brain volume differences between HIV+ males and females. With regard to HIV, we previously identified no differences between HIV+ males and females in terms of caudate volume (Ances et al. 2006) . Work by Pfefferbaum et al. (2006 Pfefferbaum et al. ( , 2007 and Ge et al. (2003) revealed no gender-specific brain volume differences among HIV+ individuals. Our current study extends this literature by investigating additional regions of interest including both cortical and subcortical brain ROIs and providing additional evidence that HIV confers insult to the brain similarly in both genders.
Conclusions regarding the impact of gender and HIV on brain integrity should be tempered by several limitations of the present study. The first limitation is the limited battery of neuropsychological tests, specifically in the verbal learning and psychomotor/processing speed domains where other studies have shown gender differences using alternative measures (or more extensive batteries) (see Martin-Thormeyer 2009 for review and Martin et al. 2011) . Therefore, the use of more psychomotor/processing tasks that fully capture the range of abilities in this domain may be useful to detect a potential difference in cognitive performance between genders. Additionally, factors including lifetime substance abuse and HIV-related comorbidities may play a role in brain volume and cognitive differences between males and females that have been observed in previous studies (Maki et al. 2015; Bouwman et al. 1998 ). In the current study, we excluded individuals with current substance abuse but we did not specifically adjust for substance abuse history in our analyses.
In summary, results from the present study provide additional evidence of neuropsychological and neuroimaging abnormalities in HIV+ individuals on stable HAART; however, there were no significant differences between males and females within the HIV+ cohort. The study highlights the importance of clinical outcomes for both males and females infected with HIV as cognitive difficulties were present despite stable HAART with a majority having viral suppression. Consistent with other studies, results from the present investigation highlight the persistence of neuropsychological impairments in the HAART era.
